US Patent Issued to Boehringer Ingelheim International on Jan. 13 for "Macrocyclic compounds and derivatives as EGFR inhibitors" (Austrian, German Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,522,615, issued on Jan. 13, was assigned to Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany).

"Macrocyclic compounds and derivatives as EGFR inhibitors" was invented by Harald Engelhardt (Ebreichsdorf, Austria) and Dietrich Boese (Erzhausen, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention encompasses compounds of formula (I) wherein the groups R1 to R3, A, B andp and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment...